ライフサイエンスコーパス: contrast enhancement

1 tems, where it can perform such functions as contrast enhancement.

2 clearly colocalized with the initial site of contrast enhancement.

3 ogenous carotenoids with nonlinear PA and PT contrast enhancement.

4 gered, the gaseous phase provides ultrasound contrast enhancement.

5 derwent MRI examination before and after the contrast enhancement.

6 n LGGs was based on (18)F-FDG uptake and MRI contrast enhancement.

7 ties, but few options for genetic control of contrast enhancement.

8 tion of PML lesions by use of MRI, including contrast enhancement.

9 ed during the late hepatic arterial phase of contrast enhancement.

10 ly during the late hepatic arterial phase of contrast enhancement.

11 cts at high resolution by delayed myocardial contrast enhancement.

12 in vivo r1 values and afforded excellent MR contrast enhancement.

13 (BBB) breakdown revealed by gadolinium (Gd) contrast enhancement.

14 cortical networks, serving such functions as contrast enhancement.

15 characterised by restricted diffusion and no contrast enhancement.

16 indeterminism are motion artifacts and poor contrast enhancement.

17 eighted signal intensity, and rapid moderate contrast enhancement.

18 encephalopathy syndrome by virtue of intense contrast enhancement.

19 rtery stent patency on the basis of measured contrast enhancement.

20 osed by using dynamic first-pass and delayed contrast enhancement.

21 lobal signal processing, such as large-scale contrast enhancement.

22 esions, a phase rim colocalized with initial contrast enhancement.

23 pe was defined by the presence or absence of contrast enhancement.

24 esions and central areas of necrosis without contrast enhancement.

25 d the first in vivo use of Eu(II) to provide contrast enhancement.

26 -weighted MR imaging demonstrated peripheral contrast enhancement.

27 rmine seven parameters characterizing tissue contrast enhancement.

28 leaks showed significantly earlier mean peak contrast enhancement (0.28 second +/- 0.83) compared wit

29 nsity (27/32), T2 hyperintensity (25/32) and contrast enhancement (20/20).

30 as most often motion (74%), followed by poor contrast enhancement (40%).

31 BVs collocated with hypoxia (81.3%) and with contrast enhancement (46.5%).

32 ated by using three indexes: (a) duration of contrast enhancement achieved within 80% of the peak (80

33 n, patient medication, radiation protection, contrast enhancement, acquisition and reconstruction par

34 od volume [CBV]), and vascular permeability (contrast enhancement after gadolinium injection) were an

35 s potential magnetic resonance imaging (MRI) contrast enhancement agents.

36 -DTPA, and PIP-DOTA possess potential as MRI contrast enhancement agents.

37 Application of the contrast-enhancement algorithm significantly increased t

38 ry network were generated with custom motion contrast enhancement algorithms.

39 ial and also during the late venous phase of contrast-enhancement, also lower than the normal surroun

40 sitive, but not 1:1, correlation between MRI contrast enhancement and (89)Zr-bevacizumab uptake.

41 the lesion edge, seen on MRI as centripetal contrast enhancement and a colocalized phase rim.

42 le diverticula, thickened walls with showing contrast enhancement and adjacent jejunum in the left mi

43 hout the nervous system that often generates contrast enhancement and center-surround receptive field

44 Increased positive contrast enhancement and highly accelerated acquisition

45 ce, the nanofluorophores can increase kidney-contrast enhancement and imaging-time window by approxim

46 es significant background reduction and thus contrast enhancement and is demonstrated on quantum dot-

47 Tumor contrast enhancement and mass effect predicted activatio

48 Furthermore, they exhibit much stronger contrast enhancement and much longer blood retention tim

49 luding frontal location and lesser extent of contrast enhancement and necrosis), relates them to lowe

50 ably distinguish between common postsurgical contrast enhancement and orbital tumor recurrence, and t

51 ur, homogeneous-versus-heterogeneous signal, contrast enhancement and paramagnetic susceptibility eff

52 d of being a culprit lesion with both plaque contrast enhancement and plaque thickness were estimated

53 demonstrated a significant and sustained MRI contrast enhancement and probe accumulation in tumors wi

54 Uniform vascular contrast enhancement and reduced contrast medium volume,

55 ium, and CT scanning factors associated with contrast enhancement and scan timing are presented and d

56 analysis of various factors associated with contrast enhancement and scan timing.

57 hy (MM-OCT) represents a new methodology for contrast enhancement and therapeutic interventions in mo

58 rameters (maximal lesion diameter, volume of contrast enhancement) and originating primary tumor.

59 st and adenosine-stress), viability (by late contrast enhancement), and coronary artery anatomy.

60 tical vasogenic and cytotoxic edema, partial contrast enhancement, and hyperperfusion.

61 tic MRI patterns, especially the presence of contrast enhancement, and the subcortical location may h

62 esence of haemorrhage, restricted diffusion, contrast enhancement, and vasoconstriction are all compa

63 changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose po

64 se core and hyperintense rim with or without contrast enhancement; and (2) "Motor Neuron" pattern: a

65 sted by smart molecular labeling and dynamic contrast enhancement approaches that enable new types of

66 tional capabilities like targeting and image contrast enhancement are added to the nanoparticles.

67 ons in imaging features, such as necrosis or contrast enhancement, are common.

68 etection by magnetic resonance imaging (MRI) contrast enhancement as well as targeted cancer cell the

69 nce imaging at 2 months of age and exhibited contrast enhancement, as seen in human OPG.

70 ith a BA-to-lipid ratio of 25% exhibited 30% contrast enhancement at B1=4.7muT in vitro.

71 -six lesions were considered active owing to contrast enhancement at baseline; 37 lesions (66%) in 10

72 With use of fusion imaging, glioblastoma contrast enhancement at contrast-enhanced US (regarding

73 In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline

74 successfully ablated if they demonstrated no contrast enhancement at follow-up computed tomography or

75 ast agents are promising as alternatives for contrast enhancement at T1-weighted MR imaging and have

76 rCBV up to the point of transformation, when contrast enhancement became apparent on T1-weighted imag

77 croscopic fluorescence imaging that provides contrast enhancement between normal and diseased tissue

78 ultimately induces a behaviorally expressed contrast enhancement between the two similar stimuli tha

79 T2-weighted hyperintensity and contrast enhancement both yielded 100% sensitivity but a

80 t is also shown that the spatial location of contrast enhancement can be controlled via laser polariz

81 time assessment of tumor vascularity so that contrast enhancement can be identified regardless of its

82 We also demonstrate that Eu(II)-based contrast enhancement can be observed for hours in a mous

83 eactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression.

84 The contrast enhancement capabilities in imaging and in diff

85 ond imaging with routine breath-hold delayed contrast-enhancement cardiovascular magnetic resonance (

86 can be rapidly detected by subsecond delayed contrast-enhancement cardiovascular magnetic resonance d

87 An ultrafast, delayed contrast-enhancement cardiovascular magnetic resonance t

88 und was judged semiquantitatively; low-grade contrast enhancement (CE) suggested its absence, and hig

89 The (18)F-FDG uptake pattern and MR imaging contrast enhancement (CE) varied by tumor type.

90 Beyond the leading edge of contrast enhancement cerebral perfusion varied, patients

91 The authors investigated the contrast enhancement characteristics of the coronary art

92 The CT and MR images were also assessed for contrast enhancement characteristics.

93 th pattern (chi2: P = 0.046) associated with contrast enhancement (chi2: P = 0.011).

94 otive photoacoustic imaging, with remarkable contrast enhancement compared with photoacoustic images

95 r rows and the corresponding time lag in the contrast enhancement curves and was correlated with the

96 s than 1 minute and resulted in high-quality contrast enhancement curves both at rest and stress (mea

97 A Dynamic Contrast Enhancement (DCE) protocol was used to capture

98 graded from category 3 to 4 based on dynamic contrast enhancement (DCE) score of positive; 50.0%-66.7

99 RV delayed contrast enhancement (DCE) was found in 9 (39%) of 23 pa

100 The PIZ as characterized by delayed contrast-enhancement (DE)-MRI identifies patients suscep

101 iomaterials with built-in optical signal and contrast enhancement, demonstrated here with simultaneou

102 umbar spine, ill-defined paraspinal abnormal contrast enhancement, diffuse/homogeneous contrast enhan

103 Enhanced US modalities with intravenous contrast enhancement dramatically improve vascular imagi

104 2) retained sufficient Mn(2+) to demonstrate contrast enhancement during MEMRI.

105 To achieve consistent contrast enhancement during pulmonary CT angiography, th

106 a given patient weight to achieve desirable contrast enhancement during pulmonary CT angiography.

107 er ischemia was defined as reduced or absent contrast enhancement during the portal phase.

108 s usually a hypovascular lesion, showing low contrast-enhancement during the early arterial and also

109 To distinguish RCC subtypes based on contrast enhancement features of CT images.

110 Contrast enhancement features of renal masses were evalu

111 otocol design that are necessary to optimize contrast enhancement for common clinical CT applications

112 l A, protocol B yielded significantly higher contrast enhancement for the aorta (508.6 HU vs 221.5 HU

113 red during the pancreatic parenchymal phase: contrast enhancement for the aorta, the pancreas, and th

114 uirements for molecular imaging and targeted contrast enhancement for these modalities.

115 vo experiments achieve long-lasting positive-contrast enhancement for vascular MRI in rabbits.

116 Myocardial contrast enhancement from microbubbles characteristicall

117 he CDC enables a quantitative description of contrast enhancement heterogeneity in lesions.

118 On late gadolinium contrast enhancement images, the size of infarction and

119 Contrast enhancement improves delineation of the fibrous

120 We could detect contrast enhancement in 41% (7 of 17) of the cases on th

121 It generates prominent contrast enhancement in aggressive MDA-MB-231 triple neg

122 CT showed heterogeneous contrast enhancement in all patients who received intrav

123 f the blood-brain barrier as demonstrated by contrast enhancement in cerebral adrenoleukodystrophy an

124 tionally, those structures showed noticeable contrast enhancement in CT and MRI.

125 intensity in five women, more avid and rapid contrast enhancement in five, and early contrast enhance

126 reparation parameters to elicit maximal CEST contrast enhancement in healthy fibroglandular breast ti

127 PA showed topical and wound interface contrast enhancement in human subjects after cataract su

128 e these nanoparticles, showing high negative-contrast enhancement in magnetic-resonance imaging (MRI)

129 x-ray mammography, characteristic pattern of contrast enhancement in MR examination or less strain in

130 ion of malignant progression than changes of contrast enhancement in MR imaging (accuracy, 81% vs. 63

131 signal intensity, milk duct appearance, and contrast enhancement in normal and tumor-containing brea

132 in plaque was evaluated as an acute, and non-contrast enhancement in plaque was evaluated as a chroni

133 Contrast enhancement in plaque was evaluated as an acute

134 function, first-pass perfusion, and delayed contrast enhancement in remote myocardium and microinfar

135 Contrast enhancement in sensory systems often relies on

136 ducts in seven, and rapid initial glandular contrast enhancement in seven.

137 re biocompatible and can produce significant contrast enhancement in T2-weighted MRI.

138 Intravascular contrast enhancement in the abdominal aorta and brachioc

139 The most common overall pattern was contrast enhancement in the border of the PML lesion wit

140 CLIO-VT750 FMT signal coregistered with contrast enhancement in the hypokinetic infarct on MRI.

141 nd that CREKA-Tris(Gd-DOTA)3 provides robust contrast enhancement in the metastatic tumours and enabl

142 Median contrast enhancement in the pulmonary artery was 8.9% lo

143 ending aorta achieved a significantly higher contrast enhancement in the pulmonary trunk with a mean

144 ombination of electronic cleansing and bowel contrast enhancement in the range of 300-500 HU results

145 locus for mechanisms of light adaptation and contrast enhancement in the retina.

146 monstrates at least a 2-second delay in peak contrast enhancement in the right or left vertebral arte

147 ) showed persistent (up to at least 2 hours) contrast enhancement in the vascular branches (Mn(2+) co

148 Neovascular contrast enhancement in Vx2 tumors (at 14 days) was 5.4%

149 Contrast enhancement increased with body weight (P < .01

150 thyltransferase promoter methylation status, contrast enhancement, initial treatment, and TTP(min) sh

151 th interval period), we found progression of contrast enhancement into the formerly hypoperfused peri

152 arameters which included the initial rate of contrast enhancement (IRE) and the maximal enhancement (

153 ant increases in rCBV up to 12 months before contrast enhancement is apparent on T1-weighted MR image

154 Strong tumour contrast enhancement is consistently observed in other t

155 g window width and window center higher when contrast enhancement is lower and vice versa.

156 The recognition that contrast enhancement is nonspecific and may not always b

157 due to hypercellular metastases, even if no contrast enhancement is observed.

158 Contrast enhancement is the most common earliest sign of

159 power or color Doppler US performed without contrast enhancement, is better able to depict and disti

160 The PCA-based method can quantify contrast enhancement kinetics of BP semiautomatically, a

161 This might influence the interpretation of contrast enhancement kinetics of breast lesions and curr

162 ct assessment of vascular function by direct contrast enhancement-magnetic resonance imaging showed t

163 of their fluorescence allows for substantial contrast enhancement, making PAiRFPs advantageous over p

164 calization of brain tumors and, by virtue of contrast enhancement, malignant ones.

165 urbo field-echo MR sequences may offer a new contrast enhancement mechanism for characterization of a

166 Contrast enhancement MRI detected six of seven (86%) ani

167 Contrast enhancement MRI using Gd-DTPA provides a method

168 We employed contrast enhancement MRI with Gd-DTPA to detect HT in a

169 rated into 2 groups, those performed without contrast enhancement (n = 12,475) and those performed wi

170 ility can be used for object identification, contrast enhancement, navigation, and communication thro

171 Six MR imaging features-contrast enhancement, necrosis, contrast-to-necrosis rat

172 ging findings such as mass effect, swelling, contrast enhancement, new perivascular T2 lesions and si

173 ) from precontrast MRI and normalized marrow contrast enhancement (NMCE) following intravenous admini

174 contrast agents generates a strong positive contrast enhancement of >1 order of magnitude.

175 arkfield sensing and imaging (observed image contrast enhancement of 27 dB for the first SWEDA).

176 icantly hinder immunomicelles from providing contrast enhancement of atherosclerotic vessels in vivo.

177 rovide insight into the physiologic basis of contrast enhancement of DCIS lesions on DCE MR images: G

178 were used for therapeutic targeting and MRI contrast enhancement of experimental glioblastoma, both

179 Contrast enhancement of gadolinium-enhanced T1-weighted

180 Contrast enhancement of intracranial atherosclerotic pla

181 status contribute to a large variability in contrast enhancement of normal breast parenchyma.

182 or for assessing tissue viability from late contrast enhancement of scar tissue.

183 Significant differences in manganese-induced contrast enhancement of the area at risk, the normal myo

184 ne case demonstrated progressive homogeneous contrast enhancement of the masses such that they were i

185 ed optic nerve enlargement in 3 patients and contrast enhancement of the optic nerve in all patients.

186 re evaluated visually and quantitatively for contrast enhancement of the stomach, and in vivo images

187 ovascular but provided less than half of the contrast enhancement of the targeted agent.

188 Angiotensin II infusion increased contrast enhancement of the tumor and distal liver vesse

189 lioblastoma tumors can provide selective MRI contrast enhancement of tumor cells and targeted therapy

190 esonance imaging with an emphasis on dynamic contrast enhancement of tumors as well as detecting of m

191 n of the vertebral body, focal/heterogeneous contrast enhancement of vertebral bodies, heterogeneous

192 al contrast enhancement, diffuse/homogeneous contrast enhancement of vertebral bodies, low-grade dest

193 By contrast, enhancement of adrenergic signaling by adminis

194 In contrast, enhancement of neural activity by whisker stim

195 In contrast, enhancement of PDGF-BB-dependent proliferation

196 In contrast, enhancement of priming is a good candidate for

197 layer systems ( approximately 25 nm gave an contrast-enhancement of 42.9% compared with approximatel

198 hotic liver in 2 imaging modalities, and (2) contrast enhancement on computed tomography, magnetic re

199 nse rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days o

200 Contrast enhancement on imaging is highly sensitive at t

201 with bevacizumab may result in a decrease in contrast enhancement on MRI despite tumor progression.

202 The ratio of contrast enhancement on MRI to normalized PET probe upta

203 All masses revealed homogeneous contrast enhancement on postcontrast T1-weighted images.

204 nce-status score, and presence or absence of contrast enhancement on preoperative images.

205 e images show that B-GQDs induce significant contrast enhancement on the heart, liver, spleen, and ki

206 the treatment, nor in HER2 expression or in contrast-enhancement on MRI between the responders and n

207 inflammatory responses from other sources of contrast-enhancement on MRI.

208 CT tumor density, contrast enhancement, or MRI characteristics appear more

209 were analyzed: dimension, degree and type of contrast enhancement, outlines of lesions, presence of i

210 section thickness of 128 microm and an 8.9 x contrast enhancement over uniform illumination.

211 class GBM had significantly lower levels of contrast enhancement (P = .02) than other subtypes, whil

212 The pharmacokinetic contrast enhancement parameters of tumors were compared

213 IRM images, well-defined paraspinal abnormal contrast enhancement, paraspinal and epidural abscesses,

214 The qualitative analysis of contrast enhancement pattern demonstrated a similar dist

215 In one patient, the contrast enhancement pattern differed between the two mo

216 ratio (CNR) of the lesions, as well as their contrast enhancement patterns (ring, heterogeneous, homo

217 resholds at each combination of ROI size and contrast enhancement phase were calculated, and receiver

218 ctor CT image acquisition during two or more contrast enhancement phases.

219 th silica gel to simulate soft tissues, with contrast enhancement pigments added to simulate differen

220 Purpose To compare intravascular contrast enhancement produced by the manganese-based mag

221 cause of the magnetic resonance (MR) imaging contrast enhancement provided by gadolinium, this deriva

222 nship between regional ammonia retention and contrast enhancement (R=-0.93, P<0.001).

223 An inverse linear relationship between the contrast enhancement rate constant during imaging and th

224 For quantitative analysis, contrast enhancement ratio (CER), lesion-to-liver contra

225 -2.74 for the aorta-based corrected relative contrast enhancement ratio and a cutoff of 2.63-2.76 for

226 qualitative MR imaging measures such as the contrast enhancement ratio led to substantially underest

227 ging, while SNR was higher (11.6 vs 5.6) and contrast enhancement ratio was lower (1.1 vs 1.5, P = .0

228 r fossa tumors, additional use of the CBF-to-contrast enhancement ratio yielded sensitivity and speci

229 more, a cutoff of 2.42-2.72 for the relative contrast enhancement ratio, a cutoff of 2.59-2.74 for th

230 t scores, signal-to-noise ratios (SNRs), and contrast enhancement ratios were derived.

231 act thickness, 1.6 vs 2.4 mm, P < .001), and contrast enhancement ratios were similar.

232 Scanning the aortic reference with peak contrast enhancement reduces variability sufficiently to

233 the volumes of the high CBV regions and the contrast-enhancement regions.

234 re, Glu222 decarboxylation yields a 100-fold contrast enhancement relative to wild-type GFP (WT).

235 e combined advantages of robust fluorescence contrast enhancement, remarkably high uncaging cross sec

236 imilar to the pattern seen at PML-IRIS, with contrast enhancement representing the most frequent sign

237 Reflecting the interpatient differences in contrast enhancement, resected tumors exhibited dramatic

238 ) indicate signal intensity before and after contrast enhancement, respectively.

239 In seven of 16 patients, contrast enhancement resulted in greater pixel intensity

240 of the models, simulated aortic and hepatic contrast-enhancement results throughout the models were

241 The contrast-enhancement results were in agreement with resu

242 ft is both necessary and sufficient to yield contrast enhancement revealing mesoscopic proximity of l

243 Parameters of contrast enhancement, risk of aggressiveness, and nodule

244 the peak (80% DCE), (b) SD of the normalized contrast enhancement (SDNCE) measured from the beginning

245 arly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate fo

246 Grade of contrast enhancement showed predictive value in classify

247 igher baseline T1 SI tended to have a higher contrast enhancement slope.

248 ing; and-before and after gadolinium chelate contrast enhancement-T1-weighted 3-dimensional spoiled g

249 vealing a mechanism for nociceptive temporal contrast enhancement (TCE).

250 Culprit plaques had a higher degree of contrast enhancement than did nonculprit plaques (25.9%

251 nt and entheseal changes, but with much less contrast enhancement than in PsA and less bone involveme

252 Clear cell RCC (ccRCC) showed more intense contrast enhancement than other RCC subtypes.

253 significant T1 relaxation shortening and MRI contrast enhancement that is blocked by particle formati

254 In those patients with contrast enhancement, the enhancement was present in the

255 To study dynamic contrast enhancement, three mice with 4T1 tumors were im

256 s enable multiple modes of imaging, and that contrast enhancement through aggregation permits their u

257 Contrast enhancement-time curves were near-automatically

258 rast-enhanced MR angiography with comparable contrast enhancement to gadolinium-based agents and may

259 no gold particles) almost completely blocked contrast enhancement to pretreatment levels, similar to

260 e enhanced US modalities include intravenous contrast enhancement, to better visualize areas with inc

261 icularly phase imaging combined with dynamic contrast enhancement, to provide new insights in acute M

262 rected AV and aorta-based corrected relative contrast enhancement values in the corticomedullary phas

263 although anti-VEGF agents may decrease tumor contrast-enhancement, vascularity, and edema, the mechan

264 Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumo

265 Contrast enhancement was 9.3% in the lowest quintile and

266 Significant OCT contrast enhancement was achieved with improved visualiz

267 The MR contrast enhancement was also demonstrated in vivo using

268 In these patients, grade 2 contrast enhancement was associated with culprit plaques

269 Contrast enhancement was better with SHI than with power

270 f the pituitary infundibulum), and degree of contrast enhancement was calculated.

271 Plaque contrast enhancement was categorized on BB MR images (gr

272 Contrast enhancement was evaluated using a semi-quantita

273 The contrast enhancement was measured in inflamed synovial t

274 Contrast enhancement was measured in the main pulmonary

275 Late contrast enhancement was observed in only 2 patients wit

276 Comparable contrast enhancement was obtained with direct infusions

277 In previous studies, the contrast enhancement was predicted to depend on the rigi

278 Contrast enhancement was robust only when compensation w

279 In six patients, no late contrast enhancement was seen, whereas all patients had

280 f different predictors of T1 baseline SI and contrast enhancement was studied by using random-effects

281 Contrast enhancement was the most common imaging sign su

282 Late contrast enhancement was used to detect areas of myocard

283 apid contrast enhancement in five, and early contrast enhancement washout in four.

284 matinib in most cases a decrease in size and contrast enhancement were observed; the outlines of lesi

285 the most perfused area of each neoplasm and contrast enhancement were quantified with a semiquantita

286 TIRM and T1-weighted images with and without contrast enhancement were subject to assessment in coron

287 Greater contrast enhancements were seen for MRI agents that were

288 NPs showed -89.1 +/- 5.7% and -0.9 +/- 0.2% contrast enhancement, whereas in in vivo study, it is fo

289 antification of the T1 relaxation time after contrast enhancement, which can be sensitive to equilibr

290 ed by transmission electron microscopy after contrast enhancement with cationic dye fixation.

291 Conclusion Glioblastoma contrast enhancement with contrast-enhanced US is superi

292 er signal intensity and more intense initial contrast enhancement with early washout compared with no

293 We hypothesized that contrast enhancement with gadolinium-DTPA (Gd-DTPA) coul

294 Dynamic contrast enhancement with ICG was possible.

295 is of simulation-driven optimization for APT contrast enhancement with the CEST effect quantified by

296 ar appearance in the early arterial phase of contrast-enhancement, with a dynamic enhancement pattern

297 h DSC MR imaging, which revealed progressive contrast enhancement within the radiation field.

298 The time delay between contrast enhancement within the stent lumen and the endo

299 Ultrasound images showed strong RRL-MB contrast enhancement within the tumors but not the contr

300 eletion (absent vs present vs undetermined), contrast enhancement (yes vs no), age (<40 vs >/=40 year